Radiobiology

NanoTomer's New Cancer Report: Early Cancer Diagnosis and Increasing Survival Rate

Retrieved on: 
Wednesday, November 23, 2022
Quality of life, Physician, Atherosclerosis, Lung, Immunology, Lymph, Angina, PI, Nuclear medicine, Therapy, Plaque, Life, Population, Diagnosis, Lymphoma, Attention, Research report, FDG, Cervical cancer, Antibody, Patient, 3D, Research, HIV disease progression rates, Radiobiology, Breast cancer, Incidence, PET/CT, CEO, Radiation, Melanoma, AD, Nursing, PETS, Phase, Death, Nature Reviews Clinical Oncology, Ageing, Cervical, Surgeon, Medical imaging, Pharmaceutical industry, Cancer

NANOTOMER, a preclinical-stage biopharmaceutical company, comments on the treatment impact of early cancer diagnosis amidst declining deaths.

Key Points: 
  • In addition, the company emphasizes the significance of Early Cancer Diagnosis for improved treatment outcomes to enhance the declining cancer deaths.
  • David Elmaleh, Founder and Chairman of NANOTOMER, identified the falling death rate from Cancer in 2022.
  • However, a Cancer diagnosis is still a traumatic event for patients and their families as one of the leading causes of death worldwide.
  • The pharmaceutical scientist and inventor David R. Elmaleh, the patent holder for FDG used in PET/CT imaging for early cancer diagnosis, explains the new development, "Early diagnosis will impact the efficacy of treatment and improve outcome.

HotSpot Therapeutics Appoints Paul Thibodeau, Ph.D., as Chief Business Officer

Retrieved on: 
Monday, July 25, 2022
View, Multiple sclerosis, Pharmacology, Radiobiology, MIT Sloan School of Management, Hotspot, Industry, Protein, Universitate metro station, INSERM, Cell biology, Drug discovery, Therapy, Multimedia, Cancer, Biotechnology, MBA, Company, Biochemistry, Patient, Institute, Degenerative disease, Entrepreneurship, Pharmaceutical industry, Management, Novartis, Biology

BOSTON, July 25, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau, Ph.D., as Chief Business Officer.

Key Points: 
  • BOSTON, July 25, 2022 /PRNewswire/ -- HotSpot Therapeutics, Inc., a biotechnology company pioneering the discovery and development of small molecule allosteric therapies for the treatment of cancer and autoimmune diseases, today announced the appointment of Paul Thibodeau, Ph.D., as Chief Business Officer.
  • "We are very pleased to welcome Paul to HotSpot as Chief Business Officer," said Jonathan Montagu, Co-Founder and Chief Executive Officer of HotSpot Therapeutics.
  • Previously, he held numerous business development positions with increasing responsibilities at Sanofi Genzyme across its oncology, transplant and multiple sclerosis franchises.
  • HotSpot Therapeutics, Inc. is targeting naturally occurring pockets on certain proteins that it refers to as "natural hotspots" that are decisive in controlling cellular protein function.

Immune Therapeutics, Inc. Announces Expansion of its Board of Directors

Retrieved on: 
Friday, June 3, 2022
COVID-19, National Multiple Sclerosis Society, Company, Board of directors, Scientist, Marketing, Research, Biomedical Research, Hematology, OTC, Board for International Food and Agricultural Development (BIFAD), Public health, University of California, San Francisco, CEO, Radiobiology, AdventHealth Orlando, Innovation, Harvard T.H. Chan School of Public Health, Solution, University, La Jolla Institute for Immunology, Therapy, Palliative care, GLOBE, National, DNA, Yale New Haven Hospital, Harvard School of Dental Medicine, Board, DNA repair, Director, Stanford University, Institute, Yale School of Medicine, Biophysics, Medical device, Management, Pediatrics, Cancer, Microbiology, Central Florida

Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive management.

Key Points: 
  • Dr. Wilson is a trained immunologist with more than 25 years of experience in biomedical research and executive management.
  • He is the Chief Innovation Officer of Statera Biopharma, Inc. and an Associate Clinical Professor at the University of California, San Diego.
  • Dr. Selsky is board certified in Pediatrics, Pediatric hematology and oncology and Palliative medicine.
  • Kevin Phelps, CEO commented; We are pleased to welcome our new members to the Board.

New Studies Published Comparing BIO 300 to Neulasta® for Acute Radiation Syndrome

Retrieved on: 
Tuesday, April 26, 2022
Research, Radiology, Contracts, Pharmaceutical, Oncology, Law Enforcement, Emergency Services, Defense, Clinical Trials, Science, Biotechnology, Other Science, Health, ARS, CEO, Injury, Clinical trial, United States Department of Defense, COVID-19, BIO, International Journal of Radiation Biology, Radiobiology, Outline of health sciences, Acute radiation syndrome, Patient, Uniformed Services University of the Health Sciences, Canadian International Council, Organizational structure of the United States Department of Defense, Emergency Use Authorization, Radiation, FDA, Lung cancer, Bone marrow failure, Cancer, Survival, Medical imaging, Pharmaceutical industry, Humanetics

A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.

Key Points: 
  • A recently published paper in the International Journal of Radiation Biology details results from a series of studies conducted with Humanetics Corporations (Humanetics) new radioprotective drug, BIO 300.
  • This nonclinical research showed that giving BIO 300 prior to exposure to lethal levels of radiation improved survival equal to Neulasta, which is given after exposure.
  • Exposure to radiation can lead to acute radiation syndrome (ARS), which involves a multitude of injuries, including bone marrow failure.
  • BIO 300 is also in clinical development for oncology applications to protect cancer patients from unintentional side effects caused by radiation therapy.

ILiAD Biotechnologies Receives NIH Grant to Develop Novel Tuberculosis Vaccine using proprietary B-Tech Vector Platform

Retrieved on: 
Tuesday, April 26, 2022
Biotechnology, General Health, Other Health, Health, Pharmaceutical, NIH, Lists of diseases, Bacteria, Vaccine, Memory B cell, Program, Infection, Review, Technology, Commissariat, BCG, Antigen, Radiobiology, Forward-looking statement, Investment, Ministry of Social Affairs, Ministry, Iliad, Medical research, Private Securities Litigation Reform Act, Moral and National Education controversy, Environment, Whooping cough, Fast track (FDA), Disease, Lists of publishing companies, National Institute of Allergy and Infectious Diseases, Tuberculosis, Medicine, Behavior, Twitter, WHO, TB, National, Bharath Institute of Higher Education and Research, Industry, Virus, Pasteur Institute, Cancer, Link, CEA, Genomics, Pasteur Institute of Lille, Person, NIAID, Parasitism, Bordetella pertussis, Innovation, National Institute, Diabetes, Degenerative disease, Pharmaceutical industry, Research, Biology, Health

ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.

Key Points: 
  • ILiADs B-Tech Vector Platform utilizes a proprietary attenuated Bordetella pertussis (B. pertussis) strain as an intranasal vaccine vector to express pathogen target antigens, inducing both systemic and respiratory mucosal immunologic responses.
  • B-Tech Vector Platform vaccines have demonstrated immunogenicity in 8 peer-reviewed published pre-clinical studies targeting viruses, bacteria, and parasites.
  • In addition to preclinical development of B-Tech Vector vaccines for TB and other targets, ILiAD continues to advance its BPZE1 pertussis vaccine through late-stage clinical development.
  • ILiAD Biotechnologies is utilizing its B-Tech technology to develop next generation vaccines to prevent infectious diseases and improve lives.

Curie Therapeutics Appoints Kapil Dhingra, MBBS, to Board of Directors

Retrieved on: 
Thursday, February 3, 2022
Biotechnology, Health, Radiology, Pharmaceutical, Oncology, Other Science, Medical Devices, Research, Hospitals, Science, Clinical Trials, Diamond, Growth, Advanced Accelerator Applications, Leadership, Faculty, Radiobiology, American Board of Nuclear Medicine, All India Institute of Medical Sciences, New Delhi, Therapy, Elgin Mental Health Center, MBBS, Roche, PSMA, Cancer, Hematology, Indiana University School of Medicine, University, Memorial Sloan Kettering Cancer Center, MD Anderson Cancer Center, Clinical research, Medicine, Emory University School of Medicine, Board, Board of directors, Ministry of Education (Malaysia), Radiopharmaceutical, Radiochemistry, Industry, Oncology, YM Biosciences, Eli Lilly, Curie, Pharmaceutical industry

Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors.

Key Points: 
  • Curie Therapeutics Inc. ("Curie"), a biotechnology company focused on developing precision radiopharmaceutical therapies for solid tumors, today announced the appointment of Kapil Dhingra, MBBS, to its Board of Directors.
  • I am excited to welcome Kapil to our Board of Directors, said Simon Read, Curies CEO and Founder.
  • Its an honor to join Curies Board of Directors, said Dr. Dhingra.
  • Dr. Dhingra serves on the Boards of Directors of Lava Therapeutics (as Chairman of the Board), Black Diamond Therapeutics, Inc., Replimune, Inc., Median Technologies, and Autolus Therapeutics plc.

CNL Launches Program to Accelerate the Development of Targeted Radiopharmaceuticals in Canada

Retrieved on: 
Thursday, November 25, 2021
CEO, Safety, Center for Drug Evaluation and Research, Chalk River Laboratories, Radiopharmaceutical, Technology, Science, Transport, Partnership, Cancer, Health, CNL, Solution, Program, Isotope, Research, Actinium-225, Investment, GLOBE, National Nuclear Laboratory, Nuclear, Organization, CNRI, SMR, Waste management, Toxicology, Radiobiology, Medicine, Pharmaceutical industry, Medical imaging, Renewable energy

The new program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through collaborative research projects related to health sciences, radiobiology and medical isotope development, by providing access to the world-class laboratories and research capabilities at the Chalk River Laboratories campus.

Key Points: 
  • The new program is designed to accelerate the development of targeted radiopharmaceuticals in Canada through collaborative research projects related to health sciences, radiobiology and medical isotope development, by providing access to the world-class laboratories and research capabilities at the Chalk River Laboratories campus.
  • Launched in 2019, the CNRI program was originally established by CNL to advance the deployment of small modular reactor (SMRs) and advanced reactor designs.
  • For the programs first intake, research proposals must align with topics that include targeted delivery systems, toxicology and pre-clinical evaluation.
  • CNL will complete a final evaluation of the proposed project plans before making the final selection and approval of successful applicants.

CNL Issues Call for Proposals for Canadian Nuclear Research Initiative

Retrieved on: 
Wednesday, September 29, 2021
Technology, Business development, Graphite-moderated reactor, Terrestrial Energy, SMR, Climate change, Solution, Science, Health, Transport, Nuclear, Ars, Chemistry, Nuclear energy, Environment, CNL, General Fusion, Program, AR, Research, CNRI, Safety, Organization, Investment, Primary energy, National Nuclear Laboratory, Radiobiology, GLOBE, Lithium, Risk management, Renewable energy

CHALK RIVER, Ontario, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canadas premier nuclear science and technology organization, is pleased to announce that it has issued a call for proposals for the third round of its Canadian Nuclear Research Initiative (CNRI) program.

Key Points: 
  • CHALK RIVER, Ontario, Sept. 29, 2021 (GLOBE NEWSWIRE) -- Canadian Nuclear Laboratories (CNL), Canadas premier nuclear science and technology organization, is pleased to announce that it has issued a call for proposals for the third round of its Canadian Nuclear Research Initiative (CNRI) program.
  • For the third intake, research proposals must align with topics that include advanced fuels, advanced materials and chemistry, reactor safety, and component development and testing.
  • Canadian Nuclear Laboratories is a world leader in nuclear science and technology offering unique capabilities and solutions across a wide range of industries.
  • For more information on the complete range of Canadian Nuclear Laboratories services, please visit www.cnl.ca or contact [email protected] .

Adamis Announces Agreement to Sell Portion of US Compounding Business

Retrieved on: 
Wednesday, August 4, 2021
Health sciences, Natural sciences, Physical sciences, Radiation therapy, Radioactivity, Radiobiology, Pharmaceutical industry, Dermatitis, Medication

The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.

Key Points: 
  • The transaction aligns with Adamis stated goal of focusing its efforts on the development of its prescription pharmaceutical pipeline.
  • Adamis expects to use the proceeds from the sale for general corporate purposes and to fund ongoing development of its pipeline.
  • Adamis is developing additional products, including treatments for acute respiratory diseases, such as COVID-19, and radiation dermatitis.
  • Certain of these risks and additional risks, uncertainties, and other factors are described in greater detail in Adamis filings from time to time with theU.S.

Radiaction Medical Ltd. Secures Additional Patents in US and Japan - En-Route to Commercialization of its Radiation Shielding Technology

Retrieved on: 
Wednesday, July 28, 2021
Radiobiology, Physical sciences, Radiation, Ionizing radiation, Radioactivity, Radiation protection, Medical physics, Nuclear physics, Fluoroscopy, Interventional cardiology, Lead shielding, StemRad

Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.

Key Points: 
  • Radiaction, is revolutionizing radiation protection by providing full-body shielding to all medical personnel during fluoroscopy-guided procedures.
  • Mounted on the C-Arm, it encapsulates the imaging beam and blocks the scattered radiation at its origin, creating a paradigm shift in medical staff radiation protection.
  • The system will initially be offered to the Interventional Cardiology (IC) and Electrophysiology (EP) markets, where physicians experience the highest radiation exposure.
  • Radiaction has been expanding its IP assets continuously, protecting key technology developments for the radiation shielding device.